Sentences with phrase «potential impact of each program»

What is the potential impact of a program like AAC on the families of participating students?

The Repayment Planner allows you to see the potential impact of each program your loan (s) are eligible for, including how your length of repayment and interest paid will change.

RGGI has never quantified the potential impacts of their program on global warming.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In developing the National OCS Program, which has also been known as a Five Year Program, the Secretary is required to achieve an appropriate balance among the potential for environmental impacts, for discovery of oil and gas, and for adverse effects on the coastal zone.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry (R) World (TM); risks related to the collection, storage, transmission, use and disclosure of confidential and personal information;

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

The VITAL Program not only assists food producers in assessing the potential impact of allergen cross contact in each of their products but also specifies a particular precautionary allergen statement to be used according to the level of cross contact identified.

Program impact pathway analysis of a social franchise model shows potential to improve infant and young child feeding practices in Vietnam

It is therefore our collective duty to ensure the actual and potential positive impacts of these programs are sustained, improved and expanded,» he said.

New York City Mayor Bill de Blasio traveled to Albany to talk about the potential cuts in Gov. Andrew Cuomo's proposed budget that would impact the Medicaid program and the City University of New York.

A few of the education items the governor did propose — such as funding for prekindergarten, mental health services, and after school programs — have the potential to make a positive impact on students»

In order to project the impact of proposed cutbacks to U.S. - funded programs in South Africa, which has the greatest prevalence of HIV infection of any country, and the west African nation of Côte d'Ivoire, which has a different kind of epidemic and a different level of foreign aid dependency, the researchers used a widely - published mathematical model along with epidemiologic and cost data from each country to project the outcomes of potential programmatic responses.

In order to evaluate the potential long - term impact of federally recommended policies, investigators used a set of criteria to select three policies to reduce childhood obesity from among 26 recommended policies: afterschool physical activity programs, a one cent per ounce excise tax on sugar - sweetened beverages (SSBs), and a ban on child - directed fast food television advertising.

In response to a question about the White House budget proposal's potential impact on NIH's ambitions, Collins pointed to passage late last year of the 21st Century Cures Act, a $ 6.3 billion measure that authorizes a decade of funding for the «moonshot» program to cure cancer, the Precision Medicine Initiative, the BRAIN initiative and efforts to combat opioid addiction.

The GoMRI is a 10 - year, $ 500 million independent research program established by an agreement between BP and the Gulf of Mexico Alliance to study the effects of the Deepwater Horizon incident and the potential associated impact of this and similar incidents on the environment and public health.

«Our research shows the potential value of nutrition education programs that take place in child care centers to impact what children eat at home.»

«Our findings point to two potential impacts from additional research — analyzing the diversity and composition of the microbiome to predict response to immunotherapy and modulating the gut microbiome to enhance treatment,» said Wargo, senior researcher on the project and co-leader of the Melanoma Moon Shot ™, part of MD Anderson's Moon Shots Program ™ to reduce cancer deaths by accelerating development of therapies from scientific discoveries.

NanoDays is a nationwide festival of educational programs about nanoscale science and engineering and its potential impact on the future.

A National Research Council (NRC) report released today lauds the additional science that could be obtained using hardware transferred to NASA from the National Reconnaissance Office (NRO) for the next large space telescope, but worries about the cost and potential impact on the balance of programs within NASA's astrophysics portfolio, especially if a coronagraph is added.

In addition, omega - 3 oils have substantial anti-inflammatory properties, and one of the most important reasons to supplement with omega 3 during the Psoriasis Program is to reduce the impact of any potential inflammatory reactions that may occur in your digestive system, your skin, and anywhere else in your body, especially if you have a chronic psoriasis which may involve considerable systemic inflammation.

«When we find that there are solutions to some of the most pressing problems in education that actually seem like they have larger appeal and potential,» says Professor Monica Higgins, faculty chair of Scaling for Impact, «we like to figure out how to help those organizations, those initiatives, those programs really scale.»

Florida's voucher program for students in the lowest - rated public schools is unconstitutional, the state supreme court ruled last week in a 5 - 2 decision that friends and foes of private school choice are scrutinizing for its potential impact on voucher debates nationwide.

Our free eBook shows how the culture of your organization, the quality of your content, and the potential of your Learning Management System are factors that have a crucial impact on the success of your eLearning programs.

Providing a hands - on experience, students who tested the device in one of the 11 trial schools found that what they did on the screen had a direct impact on hardware and that through programming and coding they learnt more about computing and hardware potential.

Candidates for the Google for Education Certified Innovator program are selected based on their professional experience, their passion for teaching and learning, their innovative use of technology in school settings, their potential to impact other educators, and their desire to tackle some of the biggest challenges in education.

Just four statewide voucher programs have been formally evaluated, and only one has shown any signs of success,» he writes, emphasizing that in no other field would policymakers move forward with such a tenuous understanding of potential impact.

This singular focus on the impact of induction programs on teacher retention has limited exploration of the potential of teacher induction programs to improve beginning teachers» instructional practices and student learning (Feiman - Nemser & Parker, 1990).

Using recent research on the impact of high «value added» teachers, the scholars estimated that the state would in the long run recoup all but 5 percent of program costs through taxes on the higher income potential of students taught by these effective teachers.

In order to evaluate the potential fiscal impact of the Nevada ESA program on the state and school districts, I chose to consider the impact of $ 1 million spent on the program.

Understanding the potential impact of the systemic use of coaching, the UF Lastinger Center has created, field - tested, and perfected a portfolio of research - driven coaching programs to advance learning in a range of areas and subjects and is offering access to them through a new Coaching Academy.

To demonstrate the potential impact of school choice on state budgets, this paper draws from legislative and independent evaluations of the fiscal effects of such programs in the states that have enacted or are contemplating enacting them.

Previous work on the impact of philanthropy in education terms these types of status quo investments as «lower leverage» grants, which can include funding for efforts in professional development, unrestricted or general purpose grants to schools, or special - purpose grants to fund a particular program or activity (e.g. arts enrichment).4 The contrasting approach — the «higher leverage» investment — is investment with the potential to exert systemic influence on public education, which can be divided into two broad categories: 5

Extensive Federal requirements and guidance call for transportation planners to evaluate potential economic, community, and environmental impacts of transportation programs; examine past trends and future projections for travel demand for people, goods, and information; and address societal issues such as community values and goals.

Part of the potential frugality is the Eco mode in Multi-Sense, diminishing the impact of your foot on the accelerator and shutting down electrically powered gizmos such as the front seats» massage program.

(39 kg) raise the child into the adult belted zone • Anti-lock brakes (ABS) modulate the brakes for the driver to provide steering control while braking • Electronic Stability Program (ESP) applies selective braking or throttle reduction to control oversteer and understeer • Brake Assist ensures maximum braking action during panic stops • Traction Control reduces the throttle and / or applies selective braking to optimize traction during acceleration • Electronic Roll Mitigation determines when the vehicle is in a potential roll over condition and applies appropriate braking force to reduce the likelihood that such an event will occur • Rollover Sensing deploys seat - mounted side air bags, side - curtain air bags and seat - belt pretensioners • Trailer Sway Control helps maintain vehicle and trailer system stability by applying selective braking • Event Data Recorder records the nature of a malfunction or impact event for retrieval using a service diagnostic tool • Available ParkView ™ Rear Backup Camera displays the view behind the vehicle in the navigation display when backing up or parking • Tire Pressure Monitoring (TPM) alerts drivers to low tire pressure (s) to facilitate safe handling • Brake - park Interlock prevents automatic transaxle from being shifted out of Park or Neutral without first applying brakes • Side Guard Door Beams in front and rear doors provide occupant protection in the event of a side impact

Risks and uncertainties include without limitation the effect of competitive and economic factors, and the Company's reaction to those factors, on consumer and business buying decisions with respect to the Company's products; continued competitive pressures in the marketplace; the ability of the Company to deliver to the marketplace and stimulate customer demand for new programs, products, and technological innovations on a timely basis; the effect that product introductions and transitions, changes in product pricing or mix, and / or increases in component costs could have on the Company's gross margin; the inventory risk associated with the Company's need to order or commit to order product components in advance of customer orders; the continued availability on acceptable terms, or at all, of certain components and services essential to the Company's business currently obtained by the Company from sole or limited sources; the effect that the Company's dependency on manufacturing and logistics services provided by third parties may have on the quality, quantity or cost of products manufactured or services rendered; risks associated with the Company's international operations; the Company's reliance on third - party intellectual property and digital content; the potential impact of a finding that the Company has infringed on the intellectual property rights of others; the Company's dependency on the performance of distributors, carriers and other resellers of the Company's products; the effect that product and service quality problems could have on the Company's sales and operating profits; the continued service and availability of key executives and employees; war, terrorism, public health issues, natural disasters, and other circumstances that could disrupt supply, delivery, or demand of products; and unfavorable results of other legal proceedings.

If you are confused or concerned about the potential impact of Amazon's new «Kindle Unlimited» program for eBooks, a full report will be featured in the next issue of Self - Publishers Monthly, expected out August 1.

Please understand the benefits and consequences of enrolling in any debt settlement program, including potential negative credit rating impacts.

Participation in the NYSE Arca ETP Incentive Program may have potential impacts on the price and liquidity of the security.

Make sure you fully understand the potential impact of any debt relief program before you sign up.

Participation in the BATS CLP Program may have potential impacts on the price and liquidity of the security.

Debt settlement is an option for people who are in a financial harship and can not afford their monthly payments It is important to be aware that you are not making monthly payments and staying current on your debts while enrolled in a debt settlement program, so be aware of the credit impact and the potential collection harassment from your creditors.

«To determine the potential cost and impact of the program, we conducted an internal analysis to see which part of our workforce is likely to take advantage of it and how that might translate into better employee retention and attraction,» said Dave Almeda, the company's chief people officer.

With the potential budget and postponed fiscal cliff deal looming in Washington, here could be drastic spending cuts impacting thousands of government programs.

Participating in the NYSE Arca ETP Incentive Program may have potential impacts on the price and liquidity of this ETF.

Applications will be judged by a number of criteria, including originality, potential impact on animal welfare and number of animals affected, time frame, the need for the program and public engagement.

Inspired by the idea of joining together to create a place that fostered meaningful interconnectivity, as opposed to just co-locating organizations into a new building, these organizations saw the larger value and potential impact of a diverse range of people sharing space, programming, and resources.